Association of body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors

Increased body mass index has been associated with improved response to immune checkpoint inhibitors in multiple cancer types. A study at University of Texas Southwestern Medical Center found that among patients receiving immune checkpoint inhibitors for malignancies, BMI ≥ 25 kg/m² was indeed associated with improved PFS and a trend toward improved OS. However, these improved outcomes were limited to patients receiving weight-based ICI dosing. There were no significant associations of BMI with outcomes among patients receiving fixed ICI dosing.